SS-31 (Elamipretide): How a Peptide Targets the Mitochondria

SS-31 Elamipretide Mitochondria describes a research field around a mitochondria-targeted tetrapeptide that selectively accumulates in the inner mitochondrial membrane and binds the phospholipid cardiolipin. Preclinical and clinical studies have investigated how this binding influences cristae architecture and the efficiency of the respiratory chain. This guide summarizes the evidence on a purely scientific basis; it is not a usage recommendation.

What Is SS-31 (Elamipretide) and How Does It Act on the Mitochondria?

SS-31 Elamipretide Mitochondria are best explained through the structure of the molecule. SS-31 (synonyms: elamipretide, MTP-131, Bendavia; developer Stealth BioTherapeutics) is an aromatic-cationic tetrapeptide with the sequence D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2 and a molecular weight of roughly 640 Da. The alternating arrangement of basic and aromatic residues lets the peptide cross cell membranes without a dedicated transporter and, following the electrical potential, concentrate in the inner mitochondrial membrane.

The central finding of basic research is that SS-31 does not act indiscriminately there but interacts specifically with the mitochondria-specific phospholipid cardiolipin. A proteomics study mapped the interaction landscape and showed cardiolipin-proximal binding to components of the respiratory chain (Chavez et al., 2020). Subsequently, models described a stabilized cristae structure, better organization of the respiratory supercomplexes, and more efficient electron transport. A comprehensive review therefore classifies SS-31 as both a bioenergetic enhancer and a targeted antioxidant that reduces electron leak and thus the formation of reactive oxygen species (Int J Mol Sci, 2025). Important for context: these mechanisms come from preclinical and experimental systems and describe no effect in healthy humans.

How Does SS-31 Bind Cardiolipin in the Inner Mitochondrial Membrane?

Cardiolipin is an unusual four-chain phospholipid found almost exclusively in the inner mitochondrial membrane, where it is closely associated with the cristae and the enzyme complexes of the respiratory chain. This is exactly the structure SS-31 targets. A mechanistic paper showed that the peptide binds lipid bilayers and modulates the surface electrostatics of cardiolipin-containing membranes, described as a key component of its mechanism of action (Mitchell et al., 2020).

The practical significance of this binding lies in the role of cardiolipin as a structural scaffold. If the phospholipid is oxidatively damaged or misorganized, the cristae can flatten and the respiratory supercomplexes can drift apart; electrons escape more easily and generate reactive oxygen species. In the cited models, the SS-31 cardiolipin interaction stabilized this geometry and reduced electron leak. Unlike a classical antioxidant that scavenges free radicals only after they form, SS-31 acts further upstream, at the membrane where the radicals originate. This distinction is central to the research because it explains why SS-31 can be effective at concentrations well below those of typical radical scavengers. Here too the caveat applies: these are mechanistic findings from cell and animal models, not proven effects in humans.

Why Are Mitochondrial Peptides Like SS-31 Considered Their Own Class?

Mitochondrial peptides are a small but conceptually distinct group of research substances that, unlike many systemically distributed peptides, act specifically at the mitochondrion. SS-31 is the most clinically studied representative of the aromatic-cationic peptides that reach the cell and the inner membrane without a transporter. The appeal of this class lies in its addressing: instead of flooding an entire cell, the compound concentrates where energy metabolism and oxidative stress meet.

A second, mechanistically different mitochondrial peptide is MOTS-c, a mitochondrially encoded peptide discussed more as a metabolic signaling molecule. Readers who want to compare the two approaches will find details in the MOTS-c guide. Both share the research interest in mitochondrial function and its role in aging.

A 2025 review summarizes the structure, mechanism of action, and investigated application areas of elamipretide and lists models from primary mitochondrial myopathy, Barth syndrome, heart failure, ischemia-reperfusion, acute kidney injury, dry AMD, Leber optic atrophy, neurodegeneration, and aging (Int J Mol Sci, 2025). This breadth illustrates how universally mitochondrial dysfunction is discussed in research as a common denominator of many conditions, but it says nothing about a proven benefit in any of these indications.

What Did the MMPOWER-3 Trial Show About SS-31 Elamipretide in Mitochondrial Myopathy?

SS-31 Elamipretide Mitochondria were at the center of MMPOWER-3, the largest controlled trial of this molecule to date. In the phase 3 study, 218 adults with primary mitochondrial myopathy were randomized 1:1 and treated for 24 weeks with either 40 mg of elamipretide per day subcutaneously or placebo (Karaa et al., 2023).

The result was sobering for the developers: the trial missed both co-primary endpoints. Neither the distance covered in the six-minute walk test nor total fatigue measured on the PMMSA scale showed a statistically significant difference between verum and placebo. The central efficacy hypothesis was thus not confirmed in the broad study population.

This clarity is valuable for research because it prevents a common fallacy: a plausible mechanism at the molecular level guarantees no measurable clinical effect in a heterogeneous patient group. The preceding crossover trial MMPOWER-2 had suggested functional signals and target engagement (Karaa et al., 2020), but the leap from these signals to a hard endpoint in a larger population did not succeed. MMPOWER-3 is therefore a textbook example of why research on SS-31 must be assessed soberly despite its elegant mechanistic story.

What Role Does the Genotype-Specific Post-Hoc Analysis Play?

After MMPOWER-3 missed its primary endpoint, attention turned to subgroups. A post-hoc analysis examined whether certain genetic constellations responded differently to elamipretide than the overall population (Post-hoc MMPOWER-3, 2024). A signal emerged in the subgroup with mtDNA replisome disorders, or chronic progressive external ophthalmoplegia (CPEO).

Specifically, the analysis reported an improvement in the six-minute walk test of plus 37.3 meters under elamipretide versus minus 8.0 meters under placebo in this subgroup. That is a marked difference supporting the hypothesis that the benefit of a mitochondria-targeted peptide might depend on the underlying molecular defect.

At the same time, methodological caution is warranted. Post-hoc analyses are hypothesis-generating, not confirmatory: they search the data retrospectively for patterns and are prone to chance findings because the groups are small and not defined in advance. Such a signal is a reason to plan a targeted, prospective trial in exactly this genotype group, but it is not proof of efficacy. For the classification of SS-31, this means the blanket statement it works or it does not falls short; research is moving toward genotype-specific questions.

What Does the FDA Approval of Elamipretide Mean for Classifying SS-31?

In September 2025, elamipretide received its first approval from the US Food and Drug Administration, narrowly limited to Barth syndrome, a rare genetic disorder with disrupted cardiolipin metabolism. This approval matters for classifying the molecule because it shows that elamipretide has provided a regulatory demonstration of efficacy and safety for one specific, clearly defined indication.

Decisive, however, is the reach of that statement. The approval concerns Barth syndrome only, and a defined finished pharmaceutical product under medical supervision. It is no carte blanche for other applications and cannot be transferred to general mitochondrial questions, aging, or performance. In particular, it does not mean that an SS-31 preparation traded as a research substance replaces the approved medicine or treats a mitochondrial disease. For primary mitochondrial myopathy, the broader field of investigation, there is precisely no positive primary endpoint (see MMPOWER-3).

The correct reading is therefore: the FDA approval confirms the basic pharmacological legitimacy of the molecule elamipretide in a narrowly defined context, but in no way classifies the widespread use as a pure research substance as therapeutically proven. Anyone studying SS-31 in the lab works outside any approved indication and without any evidence of human benefit.

What Did the TAZPOWER Study on Barth Syndrome Show Over 168 Weeks?

The basis of the later approval included TAZPOWER, a Barth syndrome study with an open-label extension phase over 168 weeks. This long observation period is especially informative for the safety and tolerability profile (Thompson et al., 2024).

The adverse-event profile was clearly shaped by the route of administration. Because elamipretide was injected subcutaneously in the trials, injection-site reactions dominated. Most common were redness (erythema) and itching (pruritus), each in roughly 80 percent of extension-phase participants, followed by injection-site pain in about 70 percent. These reactions were predominantly mild to moderate. Severe reactions requiring dose modification were uncommon at under 5 percent, and no cardiovascular safety signal above the placebo level emerged.

For research practice, the message is unambiguous: the relevant safety topic of SS-31 is not a systemic organ risk but local tolerability at the injection site. Study protocols therefore recommend rotating the application sites (abdomen, thigh, upper arm) to reduce repeated local irritation. This observation places SS-31 among a series of subcutaneously administered peptides for which skin tolerability shapes practical handling more than systemic toxicity does.

How Does SS-31 Differ From a Classical Antioxidant?

A common misconception is that SS-31 is merely another antioxidant. The evidence suggests a more precise classification. A classical radical scavenger such as vitamin C or N-acetylcysteine acts largely non-specifically distributed and captures reactive oxygen species after they have already formed. SS-31, by contrast, concentrates at the inner mitochondrial membrane and stabilizes the cardiolipin-dependent architecture where the radicals are generated in the first place (Chavez et al., 2020).

The 2025 review explicitly describes this dual character: SS-31 acts both as a bioenergetic enhancer that improves the efficiency of ATP synthesis and as a targeted antioxidant that breaks the so-called vicious cycle of reactive oxygen species and membrane damage (Int J Mol Sci, 2025). This cycle arises when oxidized membrane lipids further destabilize the respiratory chain, which generates even more radicals.

The distinction is not purely academic. It explains why SS-31 shows effects in models at low concentrations while many general antioxidants have disappointed in clinical trials. At the same time, the caveat remains that a cleanly defined mechanism in the test tube does not automatically mean a clinical benefit, as MMPOWER-3 impressively demonstrated.

What Preclinical Aging and Cardiac Findings Exist for SS-31 and Mitochondria?

Much of the interest in SS-31 stems from aging research, since declining mitochondrial function is considered a hallmark of aging. A widely noted study in a mouse model examined whether SS-31 administration started only in old age influences cardiac function. The authors reported that late treatment restored mitochondrial function and reversed age-related cardiac dysfunction in the model (Whitson et al., 2020).

Such findings are remarkable for basic research because they suggest that mitochondrial damage is not necessarily fixed but appears at least partially reversible in models. Complementing this, medicinal chemistry is working on new SS-31 derivatives; one study described analogs of the D-Arg-dimethylTyr-Lys-Phe-NH2 scaffold that lowered inflammatory markers and increased mitochondrial ATP synthesis (SS-31 derivatives, 2024).

These preclinical results must be strictly separated from clinical reality. Animal models and cell systems are highly controlled and notoriously translate poorly to humans, as the contrast between the positive cardiac findings in the mouse model and the missed endpoint in mitochondrial myopathy shows. Readers interested in the broader connection between mitochondria and biological aging will find context in the Peptide Anti-Aging guide.

How Is SS-31 (Elamipretide) Dosed and Administered in Research?

In the clinical trials, elamipretide was consistently administered at a dose of 40 mg per day subcutaneously, including over 24 weeks in MMPOWER-3 (Karaa et al., 2023). This figure describes only the study protocol in a defined patient group under medical supervision and is expressly not a recommendation for any use outside such studies.

Pharmacologically relevant is that daily administration points to a comparatively short systemic residence time of the peptide; a once-daily schedule indicates the substance does not accumulate in the circulation over days. Readers who want to model the kinetics of such peptides can use the Half-Life Calculator for SS-31 to visualize concentration curves and accumulation across different intervals.

Practical handling includes the aforementioned rotation of injection sites among abdomen, thigh, and upper arm, since injection-site reactions are the most common adverse event. As a research substance, SS-31 is currently not listed as a purchasable product on BergdorfBio; the compound is discussed here solely within the framework of scientific classification. This transparency is deliberate, because a serious presentation of mitochondrial peptides should clearly separate documented research from a concrete product offering.

How Does SS-31 Fit Into a Mitochondrial Peptide Stack?

In discussions of longevity research, SS-31 frequently appears in the context of combined approaches that address different pathways of cell regeneration. Conceptually, such approaches are connected by the idea of considering mitochondrial function, tissue repair, and oxidative stress together rather than studying a single mechanism in isolation.

Two popular combination concepts are described in detail on BergdorfBio: the Glow Stack with a focus on skin and regenerative processes, and the Klow Stack as its variant. In the literature, SS-31 is assigned more to the mitochondrial axis, while other peptides target repair or signaling more strongly. The comparison with MOTS-c in the MOTS-c guide illustrates that even within the mitochondrial peptides, different modes of action stand side by side.

For scientific classification, it is decisive that there are no controlled human data for such combinations. The evidence on SS-31 comes from monotherapy protocols in defined diseases, not from stack scenarios in healthy individuals. Combination ideas are therefore hypothesis-driven and belong to the realm of research planning, not proven practice. Anyone comparing peptides should always keep this limit of the evidence in mind and not confuse mechanistic plausibility with clinical proof.

Frequently Asked Questions About SS-31 (Elamipretide)

Is SS-31 the same as elamipretide?

Yes, SS-31 and elamipretide denote the same molecule; further synonyms are MTP-131 and Bendavia. It is a mitochondria-targeted tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2 that binds cardiolipin in the inner mitochondrial membrane.

Is elamipretide FDA-approved?

Elamipretide received its first FDA approval in September 2025, narrowly limited to the rare Barth syndrome. For primary mitochondrial myopathy, by contrast, the phase 3 trial MMPOWER-3 missed its co-primary endpoints. The approval applies only to a defined indication and an approved medicine, not to research substances.

Why does SS-31 act specifically at the mitochondria?

Through its aromatic-cationic structure, SS-31 crosses membranes without a transporter and follows the electrical potential into the inner mitochondrial membrane, where it binds cardiolipin. In models, this stabilizes the cristae architecture and the supercomplexes of the respiratory chain.

Which side effects were reported most often in trials?

Because elamipretide was injected subcutaneously, injection-site reactions dominated. In the 168-week extension of TAZPOWER, redness and itching occurred in roughly 80 percent each, and pain in about 70 percent of participants, predominantly mild to moderate.

Can I buy SS-31 at BergdorfBio?

No. SS-31 is currently not offered as a purchasable product on BergdorfBio and is discussed solely as a research substance in a scientific context. This guide serves to classify the evidence and is not a usage recommendation.

For research purposes only. Not intended for human consumption. Scientific editing: Dr. Sieglinde Klaus